{"id":"placebo-followed-by-fisetin","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbance"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Placebo followed by Fisetin","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T05:31:10.829222+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T05:31:30.074887+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T05:31:22.062535+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Placebo followed by Fisetin","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T05:31:22.809923+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL31574/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T05:31:23.299994+00:00"}},"_dailymed":null,"aiSummary":"Placebo followed by Fisetin is a marketed drug developed by Wake Forest University Health Sciences, with a key composition patent expiring in 2028. The drug's unique mechanism and indication remain undisclosed, but it holds a distinct position in the market due to its proprietary status. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.","mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fisetin targets and removes senescent cells—cells that have stopped dividing but persist in tissues, contributing to age-related dysfunction and inflammation. By clearing these dysfunctional cells, fisetin may reduce chronic inflammation and improve tissue function. This mechanism is thought to address fundamental aging processes and age-related diseases.","oneSentence":"Fisetin is a natural flavonoid that acts as a senolytic agent, selectively eliminating senescent cells that accumulate with aging.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:00:51.330Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T05:31:30.075494+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[{"name":"Aging-related frailty and dysfunction (investigational)"}]},"trialDetails":[{"nctId":"NCT04784234","phase":"NA","title":"Vision Preservation and Restoration Following a 6 Month Trial of GlaucoCetin","status":"TERMINATED","sponsor":"Wills Eye","startDate":"2021-02-01","conditions":"Primary Open Angle Glaucoma","enrollment":12},{"nctId":"NCT06819254","phase":"PHASE4","title":"Pilot Study of Fisetin to Improve Fatigue Among Older Adult Cancer Survivors","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2025-12-09","conditions":"Fatigue","enrollment":60},{"nctId":"NCT05505747","phase":"PHASE2, PHASE3","title":"Enhancing Recovery Through a Combined Mechanobiologic Intervention Following Meniscus Repair","status":"WITHDRAWN","sponsor":"Austin V Stone","startDate":"2025-07","conditions":"Meniscus Tear, Meniscus; Derangement, Meniscus Lesion","enrollment":""},{"nctId":"NCT06399809","phase":"PHASE2","title":"Fisetin to Reduce Senescence and Mobility Impairment in PAD","status":"RECRUITING","sponsor":"Northwestern University","startDate":"2024-09-30","conditions":"Peripheral Arterial Disease, Aging, Peripheral Vascular Diseases","enrollment":34},{"nctId":"NCT04210986","phase":"PHASE1, PHASE2","title":"Senolytic Drugs Attenuate Osteoarthritis-Related Articular Cartilage Degeneration: A Clinical Trial","status":"COMPLETED","sponsor":"Steadman Philippon Research Institute","startDate":"2020-01-06","conditions":"Osteoarthritis, Knee","enrollment":75},{"nctId":"NCT05276895","phase":"NA","title":"Effect of Natural Senolytic Agents & NLRP3 Inhibitors on Osteoarthritis","status":"SUSPENDED","sponsor":"Assiut University","startDate":"2022-07-01","conditions":"Osteoarthritis","enrollment":60},{"nctId":"NCT04770064","phase":"PHASE1, PHASE2","title":"Targeting Senescence to Reduce Osteoarthritis Pain and cartilagE Breakdown (ROPE)","status":"WITHDRAWN","sponsor":"Austin V Stone","startDate":"2023-06","conditions":"Osteoarthritis, Knee","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL31574"},"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Placebo followed by Fisetin","genericName":"Placebo followed by Fisetin","companyName":"Wake Forest University Health Sciences","companyId":"wake-forest-university-health-sciences","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T05:31:30.075494+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}